Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11234113 | 0.82 | L3MBTL1 (0.63) | L3MBTL1LMNAKMT2ASMN1; SMN2POLB | |
| SCHEMBL27182555 | 0.78 | L3MBTL1 (0.46) | L3MBTL1LMNAKMT2ASMN1; SMN2POLB | |
| SCHEMBL12462804 | 0.77 | KMT2A (0.53) | L3MBTL1LMNAKMT2ASMN1; SMN2CA1 | |
| SCHEMBL23674205 | 0.76 | L3MBTL1 (0.43) | L3MBTL1LMNAKMT2ASMN1; SMN2POLB | |
| SCHEMBL11435374 | 0.76 | L3MBTL1 (0.43) | L3MBTL1LMNAKMT2ASMN1; SMN2POLB | |
| SCHEMBL9164476 | 0.74 | NLRP3 (0.67) | L3MBTL1LMNAKMT2ASMN1; SMN2POLB | |
| SCHEMBL7080904 | 0.74 | LMNA (0.43) | LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL2416593 | 0.73 | L3MBTL1 (0.45) | L3MBTL1POLBCA1CA2CA12 | |
| SCHEMBL9059808 | 0.73 | NLRP3 (0.47) | L3MBTL1LMNAKMT2ASMN1; SMN2POLB | |
| SCHEMBL9386678 | 0.73 | NLRP3 (0.47) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | L3MBTL1 3484/4885LMNA 3670/4885KMT2A 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.